15289-s-bos

130 | Chapter 8 As might be expected, there are significant associations between treatment and disease progression for both RR-lowering drugs (p<0.001) and blood thinners (p<0.001) (Table 6). Both treatments are also associated with each other and they show a significant association with the proteins of interest in this study. In addition, the RR-lowering drugs but not the blood thinners show significant interactions with LRG1, ITIH3, C4B and C1QB but not with CD14 or HRG (Table 5). An analysis of the AUROC for FH + CAD for each protein, comparing the protein as measured with the protein ‘detectable’ vs. ‘not detectable’ showed there was little difference between the two (Table 5). This analysis includes the AUROC for the total number of peptides detected and whether any of the peptides were detected. The most accurate indicator of CAD is HRG (as measured) with an AUROC of 0.922 (0.862, 0.983), but there were a number of other proteins that were very similar (see Figure 2). Figure 8.3 Area under the ROC (AUROC), estimating the predictive accuracy of each protein with CAD progression. AUC: Area under the curve; C1QB: Complement C1q subcomponent subunit B; C4B: Complement C4-B; CAD: Coronary artery disease; CD14: Monocyte differentiation antigen; CI: Confidence interval; HRG: Histidine-rich glycoprotein; ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3; LRG1: Leucine-rich alpha-2-glycoprotein.